Vnitr Lek 2007, 53(11):1164-1169

Utilisation of Glykogen Phosphorylase BB measurement in the diagnosis of acute coronary syndromes in the event of chest pain

B. Lačňák1,*, D. Stejskal1,2, L. Jedelský2, M. Karpíšek3, L. Šprongl4
1 Interní oddělení nemocnice Šternberk, přednosta prim. MUDr. Bořek Lačňák
2 Oddělení laboratorní medicíny nemocnice Šternberk, přednosta doc. MUDr. David Stejskal, Ph.D.
3 Ústav humánní farmakologie a toxikologie Farmaceutické fakulty Veterinární a farmaceutická univerzity Brno, vedoucí Ing. Michal Karpíšek
4 Centrální laboratoře Šumperské nemocnice, a.s., Šumperk, přednosta Ing. Luděk Šprongl

Introduction:
Glykogen Phosphorylase BB is considered a timely and specific marker of acute coronary syndrome. A kit for measuring Glykogen Phosphorylase BB in routine diagnosis has been released recently.


Objective of the study:
To test the utilisation of Glykogen Phosphorylase BB measurement in the diagnosis of acute coronary syndrome.

Method:
70 patients with suspected acute coronary syndrome were tested. A final diagnosis of acute coronary syndrome/non-coronary difficulties was made according to ESC/ACC/AHA criteria. Measurements of troponin I, myoglobin and GPBB in venous plasma (heparin-lithium) were taken for all probands on admission and two and six hours later.

Results:
Individuals with acute coronary syndrome (n = 52) had significantly higher levels of Glykogen Phosphorylase BB on admission and 2 hours after admission (21.9 vs 6.2; 18.7 vs 5.9 μg/l; p < 0.01). Levels of Glykogen Phosphorylase BB had a greater diagnostic effectiveness for the presence of acute coronary syndrome than levels of troponin I (threshold below ROC curve 0.89 vs. 0.78; 0.87 vs. 0.67). In the first two hours after admission, only levels of Glykogen Phosphorylase BB were included as independent variables in the regression model for the incidence of acute coronary syndrome (p

Keywords: Glykogen Phosphorylase; acute coronary syndromes; non-STEMI; coronary markers

Received: March 18, 2007; Accepted: June 12, 2007; Published: November 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lačňák B, Stejskal D, Jedelský L, Karpíšek M, Šprongl L. Utilisation of Glykogen Phosphorylase BB measurement in the diagnosis of acute coronary syndromes in the event of chest pain. Vnitr Lek. 2007;53(11):1164-1169.
Download citation

References

  1. Diagenics. Online: http://www.diagenics.de
  2. Apple FS, Wu AHB, Mair J et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin Chem 2005; 51: 810-824. Go to original source... Go to PubMed...
  3. Hofmann U, Rabitzsch G, Loster K et al. Immunenzymometric assay for the heart specific glycogen phosphorylase BB in human serum using monoclonal antibodies. Biomed Biochim Acta 1989; 48: 132-136.
  4. Kemp M, Donova J, Higham H et al. Biochemical markers of myocardial injury. Br J Anaesth 2004; 93: 63-73. Go to original source... Go to PubMed...
  5. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998; 272: 79-86. Go to original source... Go to PubMed...
  6. Mair P, Mair J, Krause EG et al. Glycogen phosphorylase isoenzyme BB mass release after coronary artery bypass grafting. Eur J Clin Chem Clin Biochem 1994; 32: 543-547. Go to original source... Go to PubMed...
  7. Mair J, Puschendorf B, Amidy J et al. Release of glycogen phosphorylase in patients with unstable angina and transient ST-T alterationsBr Heart J 1994; 72: 125-127. Go to original source... Go to PubMed...
  8. Peetz D, Post F, Schinzel H et al. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005; 43: 1351-1358. Go to original source... Go to PubMed...
  9. Rabitzsch G, Mair J, Lechleitner P et al. Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995; 41: 966-978. Go to original source...
  10. Stejskal D, Lačňák B, Jedelský L et al. The utilisation of glycogen phosphorylase BB measurement with POCT in the diagnosis of acute coronary syndromes. A comparison with results of ELISA. Biomed Papers 2007 (v recenzním řízení). Go to original source...
  11. Wu AHB, Apple FS, Gibler WB et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases. Clin Chem 1999; 45: 1104-1121. Go to original source...
  12. Achermann M. Doporučení k diagnostice a léčbě nestabilní anginy pectoris - revize 2002. Online: http://www.kardiocz.cz/index.php?&desktop=clanky&action=view&id=86
  13. Pettila I, Penttila K, Rantanen T. Laboratory diagnosis of patients with acute chest pain. Clin Chem Lab Med 2000; 38: 187-197. Go to original source...
  14. Lu Y, Yu HL, Yang S. Relationship between glycogen phosphorylase BB and cardiac ischemic area or infarction area in experimental acute myocardial infarction. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2005; 17: 433.
  15. Wu AH. The ischemia-modified albumin biomarker for myocardial ischemia. MLO Med Lab Obs 2003; 35: 36-38.
  16. Ortak M, Holle AK, Lehmann W et al. GPBB - a promising cardiac marker in early detection of acute myocardial infarction. Clin Res Cardiol 2007; 96(Suppl 1): V1917.
  17. Klabunde RE. Cardiovascular Physiology Concepts. Online: http://www.cvphysiology.com/Blood%20Pressure/BP006.htm
  18. Albert JS, Thygesen K, Altman E et al. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.